Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

April 30, 2011

Conditions
HypercholesterolemiaDyslipidemia
Interventions
BIOLOGICAL

4 mg/kg

RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.

BIOLOGICAL

0.5 mg/kg

RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.

Trial Locations (5)

66211

Vince and Associates Clinical Research, Overland Park

66212

Vince and Associates Clinical Research, Overland Park

85013

Dedicated Phase 1, Inc., Phoenix

85027

Premier Research Group Limited, Phoenix

85381

Premier Research Group, Limited, Peoria

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY